New Two-Drug attack on Tough-to-Treat digestive cancers
NCT ID NCT03539822
Summary
This trial is testing whether combining two drugs, cabozantinib and durvalumab, is safe and effective for people with advanced cancers of the digestive system. It is for adults whose stomach, esophageal, liver, or colorectal cancer has progressed after standard treatments. The goal is to see if this combination can help control the cancer for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Cancer Center
TERMINATEDWestwood, Kansas, 66205, United States
Conditions
Explore the condition pages connected to this study.